DE69425516T2 - G-CSF Analoge und Verfahren zu ihrer Herstellung - Google Patents
G-CSF Analoge und Verfahren zu ihrer HerstellungInfo
- Publication number
- DE69425516T2 DE69425516T2 DE69425516T DE69425516T DE69425516T2 DE 69425516 T2 DE69425516 T2 DE 69425516T2 DE 69425516 T DE69425516 T DE 69425516T DE 69425516 T DE69425516 T DE 69425516T DE 69425516 T2 DE69425516 T2 DE 69425516T2
- Authority
- DE
- Germany
- Prior art keywords
- analogs
- csf
- another aspect
- manufacture
- processes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/010,099 US5581476A (en) | 1993-01-28 | 1993-01-28 | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69425516D1 DE69425516D1 (de) | 2000-09-21 |
DE69425516T2 true DE69425516T2 (de) | 2001-06-13 |
Family
ID=21743861
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69425516T Expired - Lifetime DE69425516T2 (de) | 1993-01-28 | 1994-01-27 | G-CSF Analoge und Verfahren zu ihrer Herstellung |
Country Status (22)
Country | Link |
---|---|
US (6) | US5581476A (de) |
EP (8) | EP0612846B1 (de) |
JP (7) | JPH08506018A (de) |
KR (2) | KR100390338B1 (de) |
CN (3) | CN1118572C (de) |
AT (2) | ATE195552T1 (de) |
AU (2) | AU697451B2 (de) |
CA (4) | CA2239360C (de) |
DE (1) | DE69425516T2 (de) |
DK (3) | DK1482046T3 (de) |
ES (3) | ES2422269T3 (de) |
FI (2) | FI120769B (de) |
GR (1) | GR3034745T3 (de) |
HK (2) | HK1009288A1 (de) |
IL (6) | IL124112A (de) |
LU (1) | LU92265I2 (de) |
LV (1) | LV12642B (de) |
NO (3) | NO952974L (de) |
NZ (5) | NZ261765A (de) |
PT (3) | PT612846E (de) |
WO (1) | WO1994017185A1 (de) |
ZA (1) | ZA94568B (de) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
DE68925966T2 (de) * | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP3708151B2 (ja) * | 1994-12-15 | 2005-10-19 | 協和醗酵工業株式会社 | Peg化したヒト顆粒球コロニー刺激因子の定量法 |
US6273598B1 (en) * | 1996-01-22 | 2001-08-14 | Creative Biomolecules, Inc. | Computer system and methods for producing morphogen analogs of human OP-1 |
US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
EP1881005B1 (de) * | 1997-07-14 | 2013-04-03 | Bolder Biotechnology, Inc. | Derivate von G-CSF und damit zusammenhängende Proteine |
US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
US6017876A (en) * | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
CN1061992C (zh) * | 1997-11-19 | 2001-02-14 | 蒋永平 | 新的重组人粒细胞集落刺激因子及其药物组合物 |
TWI242563B (en) * | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
KR100479790B1 (ko) * | 1998-04-30 | 2005-03-30 | 타녹스 인코퍼레이티드 | G - c s f 수용체의 항진 항체 및 이를 스크리닝하는 방법 |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6979442B1 (en) | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6627186B1 (en) | 1999-01-06 | 2003-09-30 | Xencor | Nucleic acids and protein variants of hG-CSF with granulopoietic activity |
US7208473B2 (en) * | 1999-01-06 | 2007-04-24 | Xencor, Inc. | Nucleic acids and protein variants of hG-CSF with granulopoietic activity |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
PT1157037E (pt) * | 1999-01-29 | 2003-12-31 | Hoffmann La Roche | Conjugados de gcsf |
US6500418B1 (en) | 1999-02-12 | 2002-12-31 | The Washington University | Stimulating neutrophil function to treat inflammatory bowel disease |
JP2000319298A (ja) * | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
US20030022383A1 (en) * | 1999-04-06 | 2003-01-30 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7244396B2 (en) | 1999-04-06 | 2007-07-17 | Uab Research Foundation | Method for preparation of microarrays for screening of crystal growth conditions |
MXPA01009999A (es) * | 1999-04-06 | 2003-07-14 | Uab Research Foundation | Metodo para examinar las condiciones de cristalizacion en el crecimiento de cristales en solucion. |
US7247490B2 (en) | 1999-04-06 | 2007-07-24 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7250305B2 (en) | 2001-07-30 | 2007-07-31 | Uab Research Foundation | Use of dye to distinguish salt and protein crystals under microcrystallization conditions |
CA2372526A1 (en) * | 1999-05-10 | 2000-11-16 | Michael D. Wyrsta | Methods and compositions for controlled polypeptide synthesis |
US6296673B1 (en) * | 1999-06-18 | 2001-10-02 | The Regents Of The University Of California | Methods and apparatus for performing array microcrystallizations |
US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
NZ517184A (en) * | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
ES2327606T3 (es) * | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | Conjugados de g-csf. |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
GB0008563D0 (en) * | 2000-04-07 | 2000-05-24 | Cambridge Discovery Chemistry | Investigating different physical and/or chemical forms of materials |
ATE258884T1 (de) * | 2000-06-16 | 2004-02-15 | Vsi Holding As | Behälter mit faltbaren wänden |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
US7792645B2 (en) * | 2000-08-30 | 2010-09-07 | The Salk Institute For Biological Studies | Three-dimensional structure of chalcone isomerase and methods of use thereof |
US20040254351A1 (en) * | 2000-09-07 | 2004-12-16 | Beals John Michael | Hyperglycosylated polypeptides |
DK1317537T3 (da) * | 2000-09-08 | 2007-04-30 | Massachusetts Inst Technology | Sammensætninger og fremgangsmåder med G-CSF analoger |
AU2002212108A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | Single-chain multimeric polypeptides |
WO2002073373A2 (en) * | 2001-03-12 | 2002-09-19 | Board Of Regents, University Of Texas System | Ensemble-based strategy for the design of protein pharmaceuticals |
DE10112825A1 (de) * | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylierung von Wirkstoffen in wässriger Lösung |
US7670429B2 (en) | 2001-04-05 | 2010-03-02 | The California Institute Of Technology | High throughput screening of crystallization of materials |
US6998219B2 (en) * | 2001-06-27 | 2006-02-14 | University Of South Florida | Maskless photolithography for etching and deposition |
JP4444652B2 (ja) * | 2001-07-11 | 2010-03-31 | マキシゲン・ホールディングズ・リミテッド | G−csf結合体 |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040247562A1 (en) * | 2001-09-28 | 2004-12-09 | Sang Yup Lee | Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3 |
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
EP1522037A2 (de) * | 2002-05-23 | 2005-04-13 | Board Of Regents The University Of Texas System | Vorhersage der signifikanz von snps (einzelnukleotid-polymorphismen) unter verwendung von energieeigenschaften von strukturen auf ensemblebasis |
US20040007672A1 (en) * | 2002-07-10 | 2004-01-15 | Delucas Lawrence J. | Method for distinguishing between biomolecule and non-biomolecule crystals |
ATE466085T1 (de) * | 2002-09-09 | 2010-05-15 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
DE10242076A1 (de) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | HAS-Allergen-Konjugate |
BR0314227A (pt) * | 2002-09-11 | 2005-10-25 | Fresenius Kabi De Gmbh | Derivados de amido de hidroxialquila |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
EP1549350B1 (de) * | 2002-10-08 | 2008-09-24 | Fresenius Kabi Deutschland GmbH | Pharmazeutisch aktive oligosaccharid-conjugate |
AU2003303636B2 (en) * | 2002-12-26 | 2010-08-05 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
GEP20084486B (en) * | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
BRPI0412671A (pt) * | 2003-08-08 | 2006-10-03 | Fresenius Kabi De Gmbh | conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima |
US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
DK2441465T3 (da) * | 2003-10-24 | 2014-04-14 | Nora Therapeutics Inc | Præparater og fremgangsmåder til en sund graviditet |
US7220407B2 (en) * | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
US20060003008A1 (en) | 2003-12-30 | 2006-01-05 | Gibson John W | Polymeric devices for controlled release of active agents |
EP1725589A1 (de) | 2004-03-11 | 2006-11-29 | Fresenius Kabi Deutschland GmbH | Hydroxyalkylstärke-protein-konjugate, durch reduktive aminierung hergestellt |
AR048918A1 (es) * | 2004-03-11 | 2006-06-14 | Fresenius Kabi De Gmbh | Conjugados de almidon de hidroxietilo y eritropoyetina |
JP2008507294A (ja) | 2004-07-26 | 2008-03-13 | ダウ グローバル テクノロジーズ インコーポレイティド | 菌株遺伝子操作による改善されたタンパク質発現のための方法 |
WO2006055260A2 (en) | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
WO2006063300A2 (en) * | 2004-12-10 | 2006-06-15 | Genentech, Inc. | Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor |
US7790174B2 (en) | 2004-12-23 | 2010-09-07 | Merck Serono Sa | G-CSF polypeptides and uses thereof |
JP4951527B2 (ja) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | 糖peg化顆粒球コロニー刺激因子 |
KR100657749B1 (ko) * | 2005-04-13 | 2006-12-20 | 씨제이 주식회사 | 인간 과립구 콜로니 형성인자 동종체 및 그 조성물 |
WO2006128460A2 (en) * | 2005-06-01 | 2006-12-07 | Maxygen Holdings Ltd. | Pegylated g-csf polypeptides and methods of producing same |
KR100694994B1 (ko) * | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | 사람 과립구 콜로니 형성인자 동종체 |
KR100735784B1 (ko) | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물 |
JP5509444B2 (ja) * | 2005-08-15 | 2014-06-04 | ファレス ファーマシューティカル リサーチ エヌ.ブイ. | アスタキサンチンの結晶形 |
US8017315B2 (en) * | 2005-08-22 | 2011-09-13 | Dana Farber Cancer Institute, Inc. | Mitochondrial localization of MUC1 |
US20070112804A1 (en) * | 2005-11-07 | 2007-05-17 | Desimas Bruce E | Systems and methods for generating automated software workflows for biological testing |
GB0605684D0 (en) * | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
WO2008111996A2 (en) * | 2006-07-20 | 2008-09-18 | Dana-Farber Cancer Institute, Inc. | Muc1-ikb kinase complexes and their activities |
WO2008097840A2 (en) | 2007-02-02 | 2008-08-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
WO2008097844A2 (en) * | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
JP4375412B2 (ja) * | 2007-02-19 | 2009-12-02 | 株式会社デンソー | 蒸発器ユニット |
BRPI0810120A2 (pt) | 2007-04-27 | 2014-11-11 | Dow Global Technologies Inc | Processo para selecionar rapidamente hospedeiros microbianos para a identificação de certas cepas com maior rendimento e/ou qualidade na expressão de proteínas heterólogas |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CA2692585A1 (en) | 2007-07-03 | 2010-01-04 | Amgen Inc. | Measurement of protein using inclusion body dry weight |
AU2008275229B2 (en) | 2007-07-09 | 2014-11-06 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
AU2008287063B2 (en) | 2007-08-09 | 2013-10-24 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
US8758761B2 (en) * | 2007-09-30 | 2014-06-24 | University Of Florida Research Foundation, Inc. | Combination therapies for treating type 1 diabetes |
US8570393B2 (en) * | 2007-11-30 | 2013-10-29 | Cognex Corporation | System and method for processing image data relative to a focus of attention within the overall image |
EP2070950A1 (de) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkylstärkederivate und deren Herstellungsverfahren |
EP2070951A1 (de) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Verfahren zur Herstellung eines Hydroxyalkylstärkederivats mit zwei Linkern |
CN103694337B (zh) | 2008-02-08 | 2016-03-02 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
US8629104B2 (en) | 2008-02-18 | 2014-01-14 | Jiangsu Hengrui Medicine Co. Ltd. | G-CSF and water-soluble polymer conjugate |
JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
CN102223893B (zh) | 2008-07-22 | 2014-07-16 | 曼诺吉尼克斯公司 | 治疗与绝经、激素改变和关节炎相关的症状的组合物和方法 |
EP3225248B1 (de) * | 2008-07-23 | 2023-06-07 | Ambrx, Inc. | Modifizierte bovine g-csf-polypeptide und ihre verwendung |
US9151289B2 (en) | 2008-08-21 | 2015-10-06 | Cummins Inc. | Fuel pump |
EA032727B1 (ru) | 2008-10-10 | 2019-07-31 | Амген Инк. | Мутантный резистентный к протеолизу полипептид fgf21 и его применение |
CA2741065C (en) | 2008-10-17 | 2017-04-25 | Dana-Farber Cancer Institute, Inc. | Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
US9189670B2 (en) * | 2009-02-11 | 2015-11-17 | Cognex Corporation | System and method for capturing and detecting symbology features and parameters |
JP2012525847A (ja) | 2009-05-05 | 2012-10-25 | アムジエン・インコーポレーテツド | Fgf21変異体およびその使用 |
PE20120358A1 (es) | 2009-05-05 | 2012-04-26 | Amgen Inc | Mutantes fgf21 y usos de los mismos |
CA2764835A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
EP2506861A1 (de) | 2009-12-02 | 2012-10-10 | Amgen Inc. | Bindeproteine zur bindung von humanem fgfr1c, humanem b-klotho sowie humanem fgfr1c als auch humanem b-klotho |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
EP2805964A1 (de) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modifizierte Rinder-Somatotropinpolypeptide und deren Verwendungen |
NZ600363A (en) | 2009-12-21 | 2014-07-25 | Ambrx Inc | Modified porcine somatotropin polypeptides and their uses |
US8952054B2 (en) | 2010-03-15 | 2015-02-10 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of MUC1 and methods of identifying the same |
US20130130283A1 (en) | 2010-03-23 | 2013-05-23 | Imba - Institut Fur Molekulare Biotechnologie Gmbh | Methods for Identifying Inhibitors of the Type III Secretion System |
US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
TWI480288B (zh) | 2010-09-23 | 2015-04-11 | Lilly Co Eli | 牛顆粒細胞群落刺激因子及其變體之調配物 |
ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
EP2897633B1 (de) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Behandlung von schmerzen durch hemmung von usp5-deubiquitinase |
ES2756532T3 (es) | 2013-03-15 | 2020-04-27 | Gladiator Biosciences Inc | Dominios de Gla como agentes de direccionamiento |
LT6161B (lt) | 2013-09-27 | 2015-06-25 | Uab Profarma | Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas |
WO2015057724A1 (en) | 2013-10-14 | 2015-04-23 | Nora Therapeutics, Inc. | Use of g-csf for treating or preventing villitis of unknown etiology in a human female |
CA2988988A1 (en) * | 2015-06-11 | 2016-12-15 | Ambio Pharmaceuticals, Llc | Pegylated granulocyte colony stimulating factor (gcsf) |
US10947287B2 (en) * | 2015-10-19 | 2021-03-16 | Sandoz Ag | DNA coding sequence for human G-CSF |
CN108384747A (zh) * | 2018-03-05 | 2018-08-10 | 安徽省农业科学院园艺研究所 | 表达狂犬抗体的cho细胞无血清悬浮培养方法 |
WO2021068074A1 (en) * | 2019-10-08 | 2021-04-15 | Zymeworks Inc. | Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same |
CA3159912A1 (en) | 2019-12-17 | 2021-06-24 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel g-csf mimics and their applications |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS6263335A (ja) * | 1985-09-13 | 1987-03-20 | Fuji Photo Film Co Ltd | 化学反応情報の処理方法 |
US4908773A (en) * | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
DK203187A (da) * | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
EP0256843A1 (de) * | 1986-08-11 | 1988-02-24 | Cetus Corporation | Expression von G-CSF, Muteine davon und deren Verwendung |
US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
NO176799C (no) * | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid |
US4853871A (en) * | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
GB2213821B (en) * | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (en) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
ATE111921T1 (de) * | 1988-06-03 | 1994-10-15 | Chugai Pharmaceutical Co Ltd | Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung. |
US5025388A (en) * | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5218092A (en) * | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5109119A (en) * | 1989-06-06 | 1992-04-28 | Schering Corporation | Crystalline r-h-gm-csf and method |
US5265030A (en) * | 1990-04-24 | 1993-11-23 | Scripps Clinic And Research Foundation | System and method for determining three-dimensional structures of proteins |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
JP3249147B2 (ja) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
DK0546124T4 (da) * | 1990-08-29 | 2003-05-19 | Inst Genetics Llc | Hæmatopoiese-stimulatorer med flere domæner |
US5124297A (en) | 1990-12-07 | 1992-06-23 | Amoco Corporation | Olefin polymerization and copolymerization catalyst |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
JPH06506217A (ja) * | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体 |
US5157736A (en) * | 1991-04-19 | 1992-10-20 | International Business Machines Corporation | Apparatus and method for optical recognition of chemical graphics |
US5386507A (en) * | 1991-07-18 | 1995-01-31 | Teig; Steven L. | Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof |
CA2116533A1 (en) * | 1991-08-30 | 1993-03-18 | George J. Todaro | Hybrid cytokines |
JP2638359B2 (ja) * | 1991-11-26 | 1997-08-06 | 富士通株式会社 | 分子動力学法の拘束条件作成装置 |
ATE195553T1 (de) * | 1992-06-09 | 2000-09-15 | Chiron Corp | Kristallisierung von m-csf |
ES2198416T3 (es) | 1992-11-24 | 2004-02-01 | G.D. SEARLE & CO. | Polipeptidos de mutacion multiples de interleuquina-3 (il-3). |
US5772992A (en) | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
US6153183A (en) | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5424963A (en) * | 1992-11-25 | 1995-06-13 | Photon Research Associates, Inc. | Molecular dynamics simulation method and apparatus |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CA2212006A1 (en) | 1995-02-03 | 1996-08-08 | G.D. Searle & Co. | Novel c-mpl ligands |
US6017523A (en) | 1995-06-06 | 2000-01-25 | G.D. Searle & Co. | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides |
NZ320978A (en) | 1995-10-05 | 2001-03-30 | G | Hematopoietic proteins and nucleic acid sequences encoding them |
US6100070A (en) | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
CA2234059A1 (en) | 1995-10-05 | 1997-04-10 | G.D. Searle & Co. | Novel c-mpl receptor agonists |
CA2234042A1 (en) | 1995-10-05 | 1997-04-10 | G.D. Searle & Co. | Novel g-csf receptor agonists |
US6066318A (en) | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
JP2001504689A (ja) | 1996-10-25 | 2001-04-10 | ジー.ディー.サール アンド カンパニー | 多機能性キメラ造血レセプターアゴニスト |
US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
AU751498B2 (en) | 1997-04-11 | 2002-08-15 | G.D. Searle & Co. | flt3 ligand chimeric proteins |
AU6246599A (en) | 1998-09-25 | 2000-04-17 | G.D. Searle & Co. | Method of producing permuteins by scanning permutagenesis |
US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
ES2606840T3 (es) * | 2001-10-10 | 2017-03-28 | Ratiopharm Gmbh | Remodelación y glicoconjugación de factor estimulante de colonias de granulocitos (G-CSF) |
-
1993
- 1993-01-28 US US08/010,099 patent/US5581476A/en not_active Expired - Lifetime
-
1994
- 1994-01-25 NZ NZ261765A patent/NZ261765A/en not_active IP Right Cessation
- 1994-01-25 KR KR10-2001-7006530A patent/KR100390338B1/ko not_active IP Right Cessation
- 1994-01-25 WO PCT/US1994/000913 patent/WO1994017185A1/en active Application Filing
- 1994-01-25 NZ NZ332188A patent/NZ332188A/xx not_active IP Right Cessation
- 1994-01-25 NZ NZ513422A patent/NZ513422A/xx not_active IP Right Cessation
- 1994-01-25 NZ NZ314960A patent/NZ314960A/xx not_active IP Right Cessation
- 1994-01-25 JP JP6517294A patent/JPH08506018A/ja not_active Withdrawn
- 1994-01-25 CA CA002239360A patent/CA2239360C/en not_active Expired - Lifetime
- 1994-01-25 CA CA2711007A patent/CA2711007C/en not_active Expired - Lifetime
- 1994-01-25 CN CN94191031A patent/CN1118572C/zh not_active Expired - Lifetime
- 1994-01-25 AU AU60957/94A patent/AU697451B2/en not_active Expired
- 1994-01-25 CA CA002153896A patent/CA2153896C/en not_active Expired - Lifetime
- 1994-01-25 CN CN2006101014030A patent/CN1970571B/zh not_active Expired - Lifetime
- 1994-01-25 CA CA2381489A patent/CA2381489C/en not_active Expired - Lifetime
- 1994-01-25 CN CN03145268XA patent/CN1495197B/zh not_active Expired - Lifetime
- 1994-01-25 KR KR1019950703096A patent/KR100375274B1/ko not_active IP Right Cessation
- 1994-01-26 IL IL124112A patent/IL124112A/en not_active IP Right Cessation
- 1994-01-26 IL IL10844694A patent/IL108446A/xx not_active IP Right Cessation
- 1994-01-26 IL IL145994A patent/IL145994A/en not_active IP Right Cessation
- 1994-01-27 PT PT94101207T patent/PT612846E/pt unknown
- 1994-01-27 ES ES10011853T patent/ES2422269T3/es not_active Expired - Lifetime
- 1994-01-27 DK DK04019074.6T patent/DK1482046T3/da active
- 1994-01-27 EP EP94101207A patent/EP0612846B1/de not_active Expired - Lifetime
- 1994-01-27 AT AT94101207T patent/ATE195552T1/de active
- 1994-01-27 DK DK94101207T patent/DK0612846T3/da active
- 1994-01-27 ES ES04019074T patent/ES2382927T3/es not_active Expired - Lifetime
- 1994-01-27 DE DE69425516T patent/DE69425516T2/de not_active Expired - Lifetime
- 1994-01-27 EP EP04019074A patent/EP1482046B1/de not_active Expired - Lifetime
- 1994-01-27 EP EP04019073A patent/EP1482045A3/de not_active Withdrawn
- 1994-01-27 EP EP98113221A patent/EP0890640A3/de not_active Withdrawn
- 1994-01-27 ES ES94101207T patent/ES2150951T3/es not_active Expired - Lifetime
- 1994-01-27 PT PT100118538T patent/PT2345724E/pt unknown
- 1994-01-27 DK DK10011853.8T patent/DK2345724T3/da active
- 1994-01-27 EP EP99113571A patent/EP0974655A3/de not_active Withdrawn
- 1994-01-27 EP EP01128744A patent/EP1233065A1/de not_active Withdrawn
- 1994-01-27 ZA ZA94568A patent/ZA94568B/xx unknown
- 1994-01-27 AT AT04019074T patent/ATE553199T1/de active
- 1994-01-27 PT PT04019074T patent/PT1482046E/pt unknown
- 1994-01-27 EP EP99112115A patent/EP0965638A3/de not_active Withdrawn
- 1994-01-27 EP EP10011853.8A patent/EP2345724B1/de not_active Revoked
-
1995
- 1995-05-24 US US08/448,716 patent/US5790421A/en not_active Expired - Lifetime
- 1995-07-27 NO NO952974A patent/NO952974L/no not_active Application Discontinuation
- 1995-07-27 FI FI953593A patent/FI120769B/fi not_active IP Right Cessation
-
1998
- 1998-04-15 IL IL12411198A patent/IL124111A/en not_active IP Right Cessation
- 1998-07-19 IL IL12539898A patent/IL125398A0/xx not_active IP Right Cessation
- 1998-07-31 HK HK98109568A patent/HK1009288A1/xx not_active IP Right Cessation
- 1998-08-28 AU AU81970/98A patent/AU8197098A/en not_active Abandoned
-
1999
- 1999-05-03 US US09/304,186 patent/US6261550B1/en not_active Expired - Lifetime
-
2000
- 2000-05-30 NZ NZ504840A patent/NZ504840A/en not_active IP Right Cessation
- 2000-11-02 GR GR20000402433T patent/GR3034745T3/el unknown
- 2000-11-23 LV LV000158A patent/LV12642B/en unknown
-
2001
- 2001-01-03 US US09/754,532 patent/US6632426B2/en not_active Expired - Fee Related
- 2001-10-17 IL IL14599401A patent/IL145994A0/xx unknown
- 2001-12-20 US US10/032,108 patent/US7381804B2/en not_active Expired - Fee Related
-
2003
- 2003-04-02 NO NO20031497A patent/NO20031497L/no unknown
- 2003-09-25 JP JP2003333761A patent/JP2004113243A/ja not_active Withdrawn
-
2005
- 2005-04-25 US US11/113,581 patent/US8058398B2/en not_active Expired - Fee Related
- 2005-11-17 JP JP2005333253A patent/JP2006096762A/ja not_active Withdrawn
- 2005-11-17 JP JP2005333254A patent/JP2006137762A/ja not_active Withdrawn
-
2007
- 2007-11-27 HK HK07112941.8A patent/HK1107356A1/xx unknown
-
2008
- 2008-07-15 JP JP2008183538A patent/JP2009057368A/ja not_active Withdrawn
-
2009
- 2009-10-21 FI FI20090384A patent/FI123078B/fi not_active IP Right Cessation
- 2009-10-30 JP JP2009249964A patent/JP2010059170A/ja active Pending
- 2009-12-08 NO NO20093489A patent/NO20093489L/no not_active Application Discontinuation
-
2011
- 2011-04-11 JP JP2011087129A patent/JP2011207885A/ja not_active Withdrawn
-
2013
- 2013-08-12 LU LU92265C patent/LU92265I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69425516T2 (de) | G-CSF Analoge und Verfahren zu ihrer Herstellung | |
AU2790292A (en) | Viral recombinant vectors for expression in muscle cells | |
IL73785A (en) | Dna sequences encoding for human erythropoietin,vectors including it,host cells transformed by them,process for producing human erythropoietin and pharmaceutical compositions comprising it | |
EP0090505A3 (en) | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it | |
DE3689868T2 (de) | Monoklonale Antikörper gegen menschliches Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und Verwendung. | |
AU5327198A (en) | Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy | |
ATE96314T1 (de) | Veterinaere zusammensetzungen zur verwendung gegen endoparasiten und verfahren zu ihrer herstellung. | |
ATE55411T1 (de) | Menschliches antithrombin iii, dns sequenzen dafuer, expressions- und klonierungsvektoren die solche sequenzen enthalten und damit transformierte zellkulturen, verfahren zur expression von menschlichem antithrombin iii und diese enthaltende pharmazeutische zusammensetzungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8363 | Opposition against the patent | ||
8365 | Fully valid after opposition proceedings |